Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.

Potratz J, Tillmanns A, Berning P, Korsching E, Schaefer C, Lechtape B, Schleithoff C, Unland R, Schäfer KL, Müller-Tidow C, Jürgens H, Dirksen U.

Mol Oncol. 2016 May;10(5):677-92. doi: 10.1016/j.molonc.2015.12.009. Epub 2015 Dec 20.

2.

Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.

Unland R, Clemens D, Heinicke U, Potratz JC, Hotfilder M, Fulda S, Wardelmann E, Frühwald MC, Dirksen U.

Anticancer Drugs. 2015 Sep;26(8):843-51. doi: 10.1097/CAD.0000000000000256.

PMID:
26053276
3.

Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.

Unland R, Borchardt C, Clemens D, Kool M, Dirksen U, Frühwald MC.

Anticancer Drugs. 2015 Mar;26(3):301-11. doi: 10.1097/CAD.0000000000000181.

PMID:
25415657
4.

Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system.

Unland R, Kerl K, Schlosser S, Farwick N, Plagemann T, Lechtape B, Clifford SC, Kreth JH, Gerss J, Mühlisch J, Richter GH, Hasselblatt M, Frühwald MC.

J Neurooncol. 2014 Jan;116(2):237-49. doi: 10.1007/s11060-013-1313-1. Epub 2013 Nov 22.

PMID:
24264533
5.

The Zyxin-related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth.

Grunewald TG, Willier S, Janik D, Unland R, Reiss C, Prazeres da Costa O, Buch T, Dirksen U, Richter GH, Neff F, Burdach S, Butt E.

Biol Cell. 2013 Nov;105(11):535-47. doi: 10.1111/boc.201300041. Epub 2013 Sep 18.

PMID:
24033704
6.

The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.

Kerl K, Ries D, Unland R, Borchert C, Moreno N, Hasselblatt M, Jürgens H, Kool M, Görlich D, Eveslage M, Jung M, Meisterernst M, Frühwald M.

BMC Cancer. 2013 Jun 13;13:286. doi: 10.1186/1471-2407-13-286.

7.

STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors.

Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U, da Silva-Buttkus P, Neff F, Unland R, Müller-Tidow C, Zobywalski C, Lohrig K, Lewandrowski U, Sickmann A, Prazeres da Costa O, Görlach A, Cossarizza A, Butt E, Richter GH, Burdach S.

Mol Cancer Res. 2012 Jan;10(1):52-65. doi: 10.1158/1541-7786.MCR-11-0524. Epub 2011 Nov 11.

8.

Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.

Burdach S, Plehm S, Unland R, Dirksen U, Borkhardt A, Staege MS, Müller-Tidow C, Richter GH.

Cell Cycle. 2009 Jul 1;8(13):1991-6. Epub 2009 Jul 5.

PMID:
19502792
9.

EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.

Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, Quintanilla-Martinez L, Kovar H, Staege MS, Müller-Tidow C, Burdach S.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5324-9. doi: 10.1073/pnas.0810759106. Epub 2009 Mar 16.

Supplemental Content

Loading ...
Support Center